Despite their contributions to the R&D of new Ebola treatments, patients, treatment providers and endemic countries do not have reliable access

The second in a series of roundtables focused on clinical trial cost transparency

Global access to point-of-care CD4 devices and tests is under threat

MSF’s recommendations on the WHO Pandemic Prevention, Preparedness and Response Accord zero draft

Access to long-acting medicines will be key to meeting global HIV prevention and treatment targets.

This policy is a commitment to publishing research protocols, registering clinical trials on appropriate registries, and subsequently publishing clinical trial data in open access formats, in line with the WHO’s joint statement on ...

TB was the leading cause of death from a single infectious agent until the COVID pandemic. The number of people newly diagnosed with TB in 2020 fell by 18% from the previous year due to disruptions to health systems and services caused ...

The UK has tabled harmful provisions that threaten to tighten the screws on producing, supplying and exporting affordable generic medicines from India

Clinical trial cost transparency can inform evidence-based policy making and enable governments and treatment providers to regulate and negotiate prices more effectively.

The challenges and opportunities offered by increasing local production of diagnostic tests in the African region

The patent opposition mechanism is a critical public health safeguard under the Indian Patents Act

In 2020, around 1.5 million people were newly infected with HIV. Global targets endorsed at the World Health Assembly 2022 aim to reduce new HIV infections from 1.5 million to under 370,000 by 2025 and under 335,000 by 2030. In order ...

This report by Resolve to Save Lives and MSF discusses access to hypertension medicines in low- and middle-income countries, and makes recommendations to reduce hypertension prevalence globally

Recommendations to member states to strengthen resolution on clinical trials at WHA75.

MSF examined access to vaccines in South Sudan, South Africa, the Philippines, Niger, and Greece

MSF comments on the reported draft text of the TRIPS Waiver ‘Quad’ negotiation

Diagnostic and treatment checklist for the management of HIV and advanced HIV disease in outpatient settings

MSF Access Campaign and People’s Health Movement on intellectual property (IP) barriers to COVID-19 vaccines and treatments in South Africa

Analysis of the COVAX Facility and the need for radical change in making COVID-19 vaccines accessible to the world

Liposomal amphotericin B is a lifesaving treatment for several diseases. Collaborative work among stakeholders is essential to overcome persistent access barriers.